REGEN BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7 USD | +23.28% |
|
+20.69% | -26.32% |
Financials (USD)
| Sales 2022 | 236K | Sales 2023 | 237K | Capitalization | 6.33M |
|---|---|---|---|---|---|
| Net income 2022 | 2M | Net income 2023 | 1M | EV / Sales 2022 | 144 x |
| Net Debt 2022 | 1.22M | Net Debt 2023 | 635K | EV / Sales 2023 | 29.4 x |
| P/E ratio 2022 |
13.7
x | P/E ratio 2023 |
6.24
x | Employees | 1 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.99% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +23.28% | ||
| 1 week | +20.69% | ||
| Current month | -6.67% | ||
| 1 month | -2.78% | ||
| 3 months | +7.69% | ||
| 6 months | -61.11% | ||
| Current year | -26.32% |
1 week
0.57
0.70
1 month
0.400.89
Current year
0.401.12
1 year
0.402.55
3 years
0.40122.25
5 years
0.00122.85
10 years
0.00750.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Koos
CEO | Chief Executive Officer | 64 | 12-04-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Koos
CEO | Chief Executive Officer | 64 | 12-04-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 0.7 | +23.28% | 10,669 |
| 24-04-17 | 0.5678 | -1.05% | 1,996 |
| 24-04-16 | 0.5738 | -11.74% | 6,501 |
| 24-04-15 | 0.6501 | -7.13% | 12,503 |
| 24-04-12 | 0.7 | +20.69% | 32,111 |
Delayed Quote OTC Markets, April 18, 2024 at 03:54 pm EDT
More quotes
Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients. tCellVax is a cell-based immunotherapy that stimulates the patientâs immune system through gene silencing of NR2F6.
| 1st Jan change | Capi. | |
|---|---|---|
| -26.32% | 2.92M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.95% | 21.66B | |
| -18.35% | 20.77B | |
| -8.68% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- RGBP Stock
